Gene therapy maker Orchard Therapeutics sells to Kyowa Kirin for $387M cash as lead program awaits 2024 FDA verdict

Amber Tong

Senior Editor

Orchard Therapeutics’ gene therapies will have a new home as Japan’s Kyowa Kirin buys out the biotech for $387.4 million in cash.

Kyowa Kirin will now take over marketing of Orchard’s only product, Libmeldy (atidarsagene autotemcel or OTL-200), for a rare and fatal metabolic disorder known as early-onset metachromatic leukodystrophy. The therapy, which is already approved in the EU and UK, is set to get a decision from the FDA in March 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Gene therapy maker Orchard Therapeutics sells to Kyowa Kirin for $387M cash as lead program awaits 2024 FDA verdict

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Inside CVS Caremark’s move that broke Humira’s hold on the market

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Gene ther­a­py mak­er Or­chard Ther­a­peu­tics sells to Ky­owa Kirin for $387M cash as lead pro­gram awaits 2024 FDA ver­dict

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Pa­tient dies in Pfiz­er’s Phase 2 Duchenne mus­cu­lar dy­s­tro­phy tri­al

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Gene therapy maker Orchard Therapeutics sells to Kyowa Kirin for $387M cash as lead program awaits 2024 FDA verdict

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Inside CVS Caremark’s move that broke Humira’s hold on the market

Medical Affairs: The Critical Link Between Science, Physicians and Patients